2026-01-17 - Analysis Report
**English Report**
===============

**Company Overview**
----------------

Welltower Inc is a healthcare real estate investment trust (REIT) that invests in and operates high-quality, healthcare infrastructure properties.

**Return Rate Comparison**
----------------------

- **Review Stock (WELL)**: Cumulative return = 128.54%
- **Comparison Stock (VOO)**: Cumulative return = 93.36%
- **Divergence**: 32.40
- **Relative divergence (max: 59.00, min: -39.80)**: 73.10%
  The review stock has a higher cumulative return rate compared to the comparison stock, resulting in a significant divergence.

**Alpha, Beta Analysis**
----------------------

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|-----|-------|------|-------|
| 2016-2018 | 14.0% | 15.3% | 10.0% | 0.5 | 47.6B |
| 2017-2019 | 24.0% | 15.3% | 7.0% | 0.3 | 56.1B |
| 2018-2020 | 39.0% | 30.5% | 18.0% | 1.1 | 44.4B |
| 2019-2021 | 19.0% | 30.5% | -25.0% | 1.3 | 58.9B |
| 2020-2022 | -15.0% | 34.0% | -13.0% | 1.1 | 45.0B |
| 2021-2023 | 6.0% | 34.0% | 5.0% | 0.7 | 61.9B |
| 2022-2024 | 29.0% | 34.0% | 10.0% | 0.6 | 86.5B |
| 2023-2025 | 98.0% | 12.4% | 36.0% | 0.5 | 127.4B |

  The review stock's Alpha and Beta values have varied over time, reflecting changes in market conditions and the stock's performance.

**Recent Stock Price Fluctuations**
------------------------------

- **Close**: $191.38
- **Last-market**: $191.38 (previousClose: $188.18, change: 1.7%)
- **5-day SMA**: $188.63
- **20-day SMA**: $187.21
- **60-day SMA**: $190.40

  The review stock's recent price fluctuations are relatively stable, with a small upturn in the last market.

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**
----------------------------------------------------------------

- **Market Risk Indicator (MRI)**: 0.80
- **RSI**: 60.10
- **PPO**: 0.33
- **Hybrid Signal**: Buy (Cash 0%)
- **Risk Level**: Medium (MRI 0.80)
- **Recent (20 days) relative divergence change**: 3.10 (+: improving)
- **7-day Rank change**: 0 (0): flat
- **7-day Dynamic Expected Return change**: 0.00 (0): flat
- **Expected Return (\%)**: -1.10%
- **Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point**.

  The review stock's RSI and PPO indicators are neutral, and the hybrid signal suggests a buy opportunity. However, the expected return is low, and the review stock's recent relative divergence change is improving.

**Recent News & Significant Events**
--------------------------------

- [2026-01-16] Corning: Executing Well, But The Stock Is Priced Well Ahead Of It (NYSE:GLW) - Seeking Alpha
- [2026-01-16] PGGM Investments Has $498.93 Million Stock Position in Welltower Inc. $WELL - MarketBeat
- [2026-01-16] (WELL.DB) Stock Trading Blueprint (WELL.DB:CA) - Stock Traders Daily
- [2025-12-26] WELL vs. MPW: Which Healthcare REIT Stock is the Better Buy Now? - Yahoo Finance
- [2026-01-15] Down More Than 30% From Its High, Is Netflix a Good Buy Right Now? - The Motley Fool
- [2026-01-13] Boeing Stock Rises on a Lot of Good News. This Is Still the Most Important Bit. - Barron's

  The review stock has been mentioned in several recent news and events, which may impact its performance.

**Analyst Opinions**
-----------------

```
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.65 (~Buy)
- Opinions: 20
- Target Price (avg/high/low): 208.70 / 260.00 / 162.00
```

  The review stock has a strong buy recommendation from analysts, with a target price range of $162.00 to $260.00.

**Recent Earnings Analysis**
---------------------------

| Date | EPS | Revenue |
|------|-----|---------|
| 2025-10-28 | 0.42 | 2.06 B$ |
| 2025-07-29 | 0.46 | 1.97 B$ |
| 2025-04-29 | 0.40 | 1.86 B$ |
| 2024-10-29 | 0.74 | 1.51 B$ |
| 2025-10-28 | 0.74 | 1.51 B$ |

  The review stock's earnings have been relatively stable, with a slight decline in the most recent quarter.

**Revenue and Profitability**
---------------------------

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $2.63B | 39.99% |
| 2025-06-30 | $2.52B | 39.80% |
| 2025-03-31 | $2.39B | 38.78% |
| 2024-12-31 | $2.22B | 36.50% |
| 2024-09-30 | $2.01B | 39.70% |

  The review stock's revenue has been increasing over time, with a slight decline in the most recent quarter. The profit margin has also fluctuated.

**Capital and Profitability**
---------------------------

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $38.76B | 0.72% |
| 2025-06-30 | $35.90B | 0.84% |
| 2025-03-31 | $33.96B | 0.76% |
| 2024-12-31 | $31.96B | 0.38% |
| 2024-09-30 | $30.33B | 1.48% |

  The review stock's equity has been increasing over time, and the return on equity (ROE) has fluctuated.

**Comprehensive Analysis (Summary of previous items)**
---------------------------------------------------

The review stock has several positive factors, including a strong buy recommendation from analysts, increasing revenue, and relatively stable earnings. However, the stock's recent relative divergence change is improving, and the expected return is low. Additionally, the review stock's RSI and PPO indicators are neutral. Overall, the review stock appears to be a relatively stable and attractive investment opportunity.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.